Anticoagulation in COVID-19.

Anticoagulation in COVID-19.

Authors

DOI:

https://doi.org/10.32553/ijmbs.v5i2.1686

Keywords:

SARS-Cov-2, COVID-19, thrombosis, anticoagulation

Abstract

In 2020 declared the COVID-19 pandemic. A new SARS-Cov-2 betacoronavirus transmitted through respiratory secretions of infected people, causing lesions in the pulmonary microvasculature, endothelial activation, massive release of pro-inflammatory substances "cytokine storm", which lead to a procoagulant state and on which it will depend the development of the serious disease. The management of coagulopathy induced by COVID-19 entails stratifying the risk of thrombosis, for which heparins are the treatment of choice, especially in hospitalized patients. Low molecular weight heparin (LMWH) is the first option since its administration implies longer times and less exposure of health personnel. Unfractionated heparin is another alternative but requires laboratory controls and is sometimes not available. Heparin-induced thrombocytopenia (HIT) and bleeding are serious adverse events secondary to the use of heparin anticoagulation.

Author Biographies

Gustavo Ayo , Médico General.

Residente en Áreas Clínicas del Hospital General Docente de Calderón. Quito. Ecuador.

Dixon Zambrano, Médico General.

Residente Áreas Clínicas del Hospital General Docente de Calderón. Quito, Ecuador.

Downloads

Published

2021-02-22

How to Cite

Ochoa, X. V. ., Ayo Chipantasig, G. ., & Zambrano Palma, D. (2021). Anticoagulation in COVID-19.: Anticoagulation in COVID-19. International Journal of Medical and Biomedical Studies, 5(2). https://doi.org/10.32553/ijmbs.v5i2.1686

Issue

Section

Articles